MiR-26a functions as an endogenous inhibitor of the TGF-β1/Smad signaling pathway, and its downregulation in IPF and pulmonary fibrosis mice models leads to the upregulation of CTGF, COL1A1, and COL3A1. This evidence concerns the gene COL3A1 and pulmonary fibrosis.